Baseline Serum Uric Acid Levels Are Associated with All-Cause Mortality in Acute Coronary Syndrome Patients after
Ziliang Ye1, Haili Lu2, Manyun Long1
1Department of Cardiology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Insights
Elevated serum uric acid (UA) is linked to increased all-cause mortality in patients with acute coronary syndrome (ACS) after percutaneous coronary intervention (PCI). This finding highlights UA as a potential risk factor in ACS patients post-PCI.
Area of Science:
- Cardiology
- Biochemistry
- Clinical Research
Background:
- The association between serum uric acid (UA) and all-cause mortality in patients with acute coronary syndrome (ACS) following percutaneous coronary intervention (PCI) is not well-established.
- Understanding this relationship is crucial for risk stratification and management of ACS patients.
Purpose of the Study:
- To investigate the association between serum uric acid levels and all-cause mortality in patients with ACS after PCI.
- To determine if elevated serum UA is an independent predictor of mortality in this patient population.
Main Methods:
- A retrospective cohort study was conducted involving 2296 patients with ACS who underwent PCI.
- Curve-fitting identified a serum UA threshold of 5.6 mg/dL to stratify patients into high-UA and low-UA groups.
- Cox proportional-hazard regression models were used to analyze the association between UA levels and all-cause mortality.
Main Results:
- During a mean follow-up of 246 days, 168 patients (7.32%) died from all causes.
- The high-UA group (serum UA > 5.6 mg/dL) had a significantly higher mortality rate (9.36%) compared to the low-UA group (6.65%) (P = 0.031).
- Elevated serum UA was independently associated with an increased risk of all-cause mortality (adjusted HR = 1.42, 95% CI: 1.05 to 1.87).
Conclusions:
- Elevated serum uric acid levels (>5.6 mg/dL) are significantly associated with increased all-cause mortality in patients with ACS after PCI.
- Serum UA may serve as a valuable prognostic biomarker for identifying high-risk ACS patients post-PCI.
Background:
Whether serum uric acid (UA) is associated with all-cause mortality in patients with acute coronary syndrome (ACS) following percutaneous coronary intervention (PCI) remains unclear.
Methods:
We performed a retrospective cohort study of 2296 patients with ACS. Curve-fitting and Cox proportional-hazard regression models with a hazard ratio (HR) and 95% confidence interval (CI) were used.
Results:
During a mean follow-up of 246.31 ± 49.16 days, 168 (7.32%) patients died from all causes. Patients were divided into two groups [the high-UA group (n = 566) and the low-UA group (n = 1730)] based on the serum UA threshold value (5.6 mg/dl) identified through curve fitting. Fifty-three (9.36%) patients died in the high-UA group, and 115 (6.65%) patients died in the low-UA group. The difference between groups was statistically significant (P = 0.031). Univariate analysis showed that the risk of all-cause mortality in the high-UA group was significantly greater than that in the low-UA group (HR = 1.45, 95% CI: 1.03 to 2.04). This difference persisted after adjustment for baseline characteristics, medical history, and medication history (HR = 1.42, 95% CI: 1.05 to 1.87).
Conclusions:
Our study demonstrated that elevated serum UA (>5.6 mg/dl) is associated with all-cause mortality in ASC patients after PCI.
More Related Videos
Related Concept Videos
01:30Acute Coronary Syndrome I: Introduction
01:26Acute Coronary Syndrome V: Nursing Management
01:30Acute Coronary Syndrome III: Diagnostic Studies
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
01:21Coronary Circulation
Coronary circulation begins at the base of the aorta, where two main arteries arise—the left and right coronary arteries. These arteries encircle the heart in the coronary sulcus and supply the...